Table 1

Overview of the patients and tumours evaluated in this study

Patient	Sex	Diameter (mm)	Histology	Pre-CT	Post-CT	NE	PET/SUV	Grade	Margins
1	M	20	Carcinoid	18	60	42	4.01	G1	Lobulated
2	M	20	Carcinoid	19	35	16	6.53	G1	Lobulated
3	M	22	Adenocarcinoma	25	83	58	7.14	G1	Spiculated
4	M	21	Adenocarcinoma	15	55	40	3.05	G1	Spiculated
5	F	22	Adenocarcinoma	10	26	16	4.50	G1	Spiculated
6	F	20	Adenocarcinoma	7	30	23	5.10	G1	Spiculated
7	M	14	Adenocarcinoma	27	54	27	6.03	G2	Spiculated
8	M	15	Adenocarcinoma	46	98	52	6.03	G2	Spiculated
9	M	29	Adenocarcinoma	50	105	55	6.03	G2	Spiculated
10	F	29	Adenocarcinoma	47	90	43	3.45	G2	Spiculated
11	M	30	Adenocarcinoma	22	69	47	3.67	G2	Spiculated
12	M	30	Adenocarcinoma	32	87	55	2.55	G2	Spiculated
13	M	22	Adenocarcinoma	14	77	63	3.50	G2	Spiculated
14	M	25	Adenocarcinoma	28	58	30	5.80	G2	Spiculated
15	F	28	Adenocarcinoma	38	87	49	8.50	G2	Spiculated
16	M	26	Adenocarcinoma	48	65	17	4.40	G2	Spiculated
17	M	30	Epidermoid	34	86	52	38.22	G2	Spiculated
18	M	25	Epidermoid	17	82	65	10.20	G2	Spiculated
19	M	30	Epidermoid	75	98	23	19.50	G2	Spiculated
20	M	24	Epidermoid	42	102	60	2.10	G2	Spiculated
21	F	23	Epidermoid	39	60	21	22.40	G2	Spiculated
22	M	9.5	Adenocarcinoma	5	48	43	2.05	G3	Lobulated
23	M	22.5	Adenocarcinoma	12	44	32	12.50	G3	Lobulated
24	F	14	SCLC	57	94	37	0.10	G3	Lobulated
25	M	27	SCLC	25	47	22	5.50	G3	Lobulated
26	M	14	Adenocarcinoma	18	62	44	0.10	G3	Spiculated
27	M	28	Adenocarcinoma	43	69	26	8.13	G3	Spiculated
28	M	23	Adenocarcinoma	18	44	26	7.50	G3	Spiculated
29	M	27	SCLC	19	41	22	4.59	G3	Spiculated
30	M	26	SCLC	38	75	37	2.90	G3	Spiculated

E, net enhancement; SCLC, small cell lung cancer; SUV, standardised uptake value.